Skip to main content
NCBI home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1979 Aug 4;121(3):309–316.

Effect of captopril (SQ 14225) on blood pressure, plasma renin activity and angiotensin I converting enzyme activity.

P Larochelle, J Genest, O Kuchel, R Boucher, Y Gutkowska, D McKinstry
PMCID: PMC1704340  PMID: 223756

Abstract

Seven patients with essential hypertension and seven patients with hypertension associated with renal artery stenosis received captopril (SQ 14225), an inhibitor of angiotensin I converting enzyme. There was a significant reduction in mean blood pressure, from 176/113 +/- 4/3 mm Hg during the control period to 140/90 +/- 5/3 mm Hg during captopril administration. Five patients received captopril alone and nine patients needed hydrochlorothiazide in addition to control their blood pressure. Captopril produced a significant increase in peripheral plasma renin activity. When measured 12 hours after the administration of captopril the angiotensin I converting enzyme activity was found to be similar to that during the control period even though the blood pressure was at or near normal. These findings indicate that although captopril is an effective antihypertensive agent, its action does not depend only on inhibition of plasma angiotensin I converting enzyme activity.

Full text

PDF
309

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Case D. B., Atlas S. A., Laragh J. H., Sealey J. E., Sullivan P. A., McKinstry D. N. Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients. Prog Cardiovasc Dis. 1978 Nov-Dec;21(3):195–206. doi: 10.1016/0033-0620(78)90025-7. [DOI] [PubMed] [Google Scholar]
  2. Cushman D. W., Cheung H. S., Sabo E. F., Ondetti M. A. Design of new antihypertensive drugs: potent and specific inhibitors of angiotensin-converting enzyme. Prog Cardiovasc Dis. 1978 Nov-Dec;21(3):176–182. doi: 10.1016/0033-0620(78)90023-3. [DOI] [PubMed] [Google Scholar]
  3. Ferguson R. K., Turini G. A., Brunner H. R., Gavras H., McKinstry D. N. A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet. 1977 Apr 9;1(8015):775–778. doi: 10.1016/s0140-6736(77)92958-0. [DOI] [PubMed] [Google Scholar]
  4. Gavras H., Brunner H. R., Laragh J. H., Sealey J. E., Gavras I., Vukovich R. A. An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med. 1974 Oct 17;291(16):817–821. doi: 10.1056/NEJM197410172911603. [DOI] [PubMed] [Google Scholar]
  5. Gavras H., Brunner H. R., Turini G. A., Kershaw G. R., Tifft C. P., Cuttelod S., Gavras I., Vukovich R. A., McKinstry D. N. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med. 1978 May 4;298(18):991–995. doi: 10.1056/NEJM197805042981803. [DOI] [PubMed] [Google Scholar]
  6. Gutkowska J., Boucher R., Genest J. Dosage radioimmunologique de l'activité rénine plasmatique. Union Med Can. 1977 Apr;106(4):446–450. [PubMed] [Google Scholar]
  7. Ondetti M. A., Rubin B., Cushman D. W. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science. 1977 Apr 22;196(4288):441–444. doi: 10.1126/science.191908. [DOI] [PubMed] [Google Scholar]
  8. Williams G. H., Hollenberg N. K. Accentuated vascular and endocrine response to SQ 20881 in hypertension. N Engl J Med. 1977 Jul 28;297(4):184–188. doi: 10.1056/NEJM197707282970404. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES